Lupin launches Ganirelix Acetate injection in US
Lupin Ltd has launched the Ganirelix Acetate injection, a single-dose prefilled syringe approved by the US FDA, for women undergoing fertility treatments. The injection, a generic equivalent to Organon USA LLC, is used to inhibit premature Luteini...
By PTI | Updated:
Pharma major Lupin Ltd on Thursday said it has launched Ganirelix Acetate injection indicated to women undergoing certain fertility treatments following approval from the US health regulatory. The US Food and Drug Administration (USFDA) had approved Ganirelix Acetate injection, 250 mcg/0.5 mL, single-dose prefilled syringe and the same has been launched in the US market, Lupin said in a regulatory filing.
It is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.
The injection is indicated for the inhibition of premature Luteinizing Hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate injection had estimated annual sales of USD 87 million in the US, Lupin said citing IQVIA MAT December 2023 data.
It is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.
The injection is indicated for the inhibition of premature Luteinizing Hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate injection had estimated annual sales of USD 87 million in the US, Lupin said citing IQVIA MAT December 2023 data.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
